Cognitive Behavioral Psychopharmacology (eBook)

The Clinical Practice of Evidence-Based Biopsychosocial Integration

Mark Muse (Herausgeber)

eBook Download: EPUB

2017
John Wiley & Sons (Verlag)
978-1-119-15258-3 (ISBN)

Infos

Outlines a comprehensive, evidence-based approach to coordinating psychopharmacological and psychotherapeutic treatments 

Cognitive Behavioral Psychopharmacology takes an evidence-based approach to demonstrating the advantages of biopsychosocial integration in interventions for the major psychiatric diagnoses. It is the first and only book to translate the current evidence for cognitive behavioral, psychosocial, and pharmacologic approaches to mental health disorders into clear guidance for clinical practice.

There is a burgeoning movement in mental health to acknowledge the entire person's functioning across physical, psychological and social spheres, and to integrate medical as well as psychological and social interventions to address the entire spectrum of presenting problems. This book bridges a gap in the professional mental health literature on the subject of standalone versus combined treatment approaches. It reviews the current state of integrative care, and makes a strong case that optimal outcomes are best achieved by an awareness of how and why the cognitive-behavioral aspects of prescribed medical and psychological interventions influence treatment. Each disorder-specific chapter is authored by a prescriber and psychotherapist team who consider all the evidence around treatments and combinations, providing outcome conclusions and concise tables of recommended front-line interventions.

• Provides a biopsychsocial perspective that integrates the medical, psychotherapeutic, family, and community aspects of the therapeutic process
• Brings together and compares the current evidence for and against treatments that combine psychopharmacology and cognitive behavioral psychotherapy for major psychiatric diagnoses
• Outlines an evidence-based approach to determining which combination of treatments is most appropriate for each of the major psychiatric diagnoses
• Describes, in a way that is accessible to both prescribers and therapists, when and how cognitive behavioral therapy can be integrated into pharmacotherapy

The book will appeal to a wide range of mental health professionals, including psychologists, psychiatrists, clinical social workers, licensed professional counselors, marriage and family therapists, and addictions counselors. It also will be of interest to primary care physicians and nurse practitioners who work side by side with mental health professionals.

MARK MUSE, EDD, PHD, ABPP, MP is licensed as a prescribing medical psychologist by the Louisiana State Board of Medical Examiners. He is past president of the Maryland Academy of Medical Psychologists, and is the author of numerous articles which have appeared in professional journals of psychology and medicine, as well as the books Introduction to Cognitive-Behavioral Therapy: Theoretical Foundations and Handbook of Clinical Psychopharmacology for Psychologists.

Inhalt

Notes on Contributors vii

Foreword xi

Preface xv

1 Evidence-Based Biopsychosocial Treatment through the Integration of Pharmacotherapy and Psychosocial Therapy 1
Mark D. Muse

2 Psychoses: Evidence-Based Integrated Biopsychosocial Treatment of Psychoses 17
David Shearer, Bret A. Moore, and Christopher Brown

3 Mood Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Major Depressive Disorder 39
Mikel Merritt

4 Mood Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Bipolar Disorder 61
Randon Welton and Brenda J. B. Roman

5 Mood Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Dysthymia and Adjustment Disorder with Depression 85
Kevin McGuinness, Samuel Dutton, and Peter Smith

6 Anxiety Disorders: Evidence-Based Integrated Biopsychosocial Treatment 107
Mark D. Muse and Stephen M. Stahl

7 Personality Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Borderline Personality Disorder 137
Donald Black, Joel Paris, and Charles Schulz

8 Sleep Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Insomnia 167
Taylor Bos and Helene A. Emsellem

9 Somatoform Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Chronic, Persistent, Nonmalignant Pain 193
Douglas E. DeGood, Robert M. Julien, and Catherine A. DeGood

10 Eating Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Anorexia Nervosa, Bulimia and Binge Eating Disorder 217
Marla Sanzone

11 Evidence-Based Integrated Biopsychosocial Treatment of ADHD and Disruptive Disorders in Childhood and Adolescence 243
George Kapalka, Ronald T. Brown, David F. Curtis, Tony C. Wu, and Mario Marquez

12 Geriatric Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Depression, Dementia, and Dementia-Related Disorders in the Elderly 285
Robert E. McCue and Mary Kelleher

13 Behaviorally Prescribed Psychopharmacology: Beyond Combined Treatments to Coordinated Integrative Therapy 325
Mark D. Muse

Index 363

Textauszug

Foreword

Science of Prescribing

The need for evidenced-based treatment guidelines is more important than ever, since mental illness affects one in five adults in the US each year, with nearly 10 million adults (4% of the US adult population) suffering with mental disorders serious enough to impact one or more areas of social and occupational functioning. There are nearly 4 million patients with depression followed by primary care in the US, with nearly four out of every five prescriptions for antidepressants being written by nonpsychiatrists. Clinicians and researchers must find a way to evaluate and disseminate the best treatments, individualized for each patient.

Treatments for behavioral and mental health disorders are an evolving area of science and practice that have substantial impact on the people who suffer from them. It is estimated that 47% of the US population will suffer from one or more mental health problem during their lifetime at a cost of over $57 billion (APA, 2016; Kessler et al., 2007 ). Research indicates that up to 25% of patients in primary care suffer from a mood disorder and this substantially impacts other health issues such as diabetes and hypertension (AHRQ, 2017). Prior to the 1990s the major treatments for behavioral health problems were psychotherapies, mainly based on psychodynamic theories, which had little evidence for their effectiveness. There were a few psychotropic medications available and many of them had significant and potentially severe side effects, and could be deadly with 1 month's prescription. The “Decade of the Brain” (Library of Congress/NIMH, 2000; Morris, 2000 ), and the focus on the neural and biological mechanisms of these disorders have radically changed treatment options since the 1990s. At the same time, research on evidence-based psychotherapies has increased, and proved that behavioral and other psychosocial therapies are also effective treatments for many mental health disorders.

Following the development of Prozac and the selective serotonin reuptake inhibitors (SSRIs), which provided a relatively safe treatment option, there has been a substantial increase in the use of psychotropic medications, especially by nonpsychiatric physicians in the United States (Wang et al., 2005 , 2006 ). The National Institute of Mental Health's (NIMH) “Depression Awareness, Recognition, and Treatment (DART) Program” was a multiphase information and education program designed to educate health professionals and the general public that depressive disorders are prevalent and treatable (Regier et al., 1988 ). Part of the DART program targeted primary care physicians and coincided with the introduction of the SSRIs for treatment of depression. During the same period there was a dramatic decrease in the use of behavioral and other psychosocial therapies, despite evidence that they are effective (Wang et al., 2005 ). The increase in the use of psychotropic medications and decline in behavioral and psychotherapies is also linked to changes in reimbursement and the rise in managed mental healthcare by insurance companies (Phelps, Bray, & Kearney, 2017). The focus on either the exclusive use of psychotropic medications or the preferential use of behavioral therapies has not served the public well, and such a practice results in many people not getting the most effective treatments available. Hence the need for an integrated, evidenced-based approach.

An exciting recent study by Dunlop et al. ( 2017 ) provides enticing evidence that we are at a new and important watershed in our understanding of effective therapies for mental illness. This group has identified how to use imaging techniques like functional magnetic resonance imaging (MRI) to differentiate probable remission of depressive symptoms or failure of treatment with either cognitive-behavioral therapy (CBT) or medication before treatment by identifying “brain subtypes” in their research sample of patients with depression.

It is not very often that a book comes along that provides a new and innovative way to integrate two areas of science and practice, while providing a comprehensive and valuable review of the literature. Most books on psychopharmacology focus on the neurobiological aspects of medications and their use with specific disorders. There is relatively little about integration of how the psychosocial impact of taking a medication impacts its functioning and effectiveness, nor have psychopharmacology texts seriously looked at the science of prescribing; rather, they tend to focus on the chemical prescribed and its impact on symptoms. In this volume Muse and colleagues break away from the unidimensional, one-sided analysis of psychopharmacology as a stand-alone intervention. Indeed, they go even further by exploring the relative value of psychotherapy, and by integrating psychosocial interventions with pharmacotherapy according to the evidence at hand. There are chapters on each of the major categories of mental and behavioral health problems that review the existing literature and provide recommendations for the appropriate use of psychotropic medications and behavioral therapies for these disorders. What is refreshing is the perspective on the integration of the two approaches, while relying on the existing evidence for making recommendations.

The first chapter by Mark Muse provides an overview and summary of each of the chapters in the book. He provides a conceptual framework to understand the chapters and outlines the criteria for the evidence-based reviews that rely on the recommendations of Sackett, Rosenberg, Gray, Haynes, and Richardson ( 1996 ). He then summarizes the major, first-line recommendations for each of the disorders. This chapter alone is worth the price of the book and is an excellent reference chapter. The remaining chapters provide in-depth coverage of all recommended treatments, first-line, as well as secondary and tertiary treatments, for all major mental conditions that are seen in behavioral health and general medical settings. The last chapter by Dr. Muse provides an innovative perspective on integrating behavioral perspectives and the science of prescribing with psychopharmacology. This book will serve as an important reference for a variety of healthcare providers. All of the many authors who collaborated on this project are to be congratulated for developing a framework on integrating behavioral therapies with psychopharmacology. This integration fits well with the move toward an integrated healthcare system in the United States.

Cognitive Behavioral Psychopharmacology: The Clinical Practice of Evidence-Based Biopsychosocial Integration is an important collaborative step in the push toward a clearer understanding of the interplay between psychopharmacology and psychotherapy, with an ever-diligent eye toward evidence-based decision-making. The chapters follow the format of reviewing the literature concerning effective psychotherapies, psychopharmacological interventions, and combinations of both for each diagnostic category, managing to include the relevant meta-analyses and randomized clinical trials down to case reports, rounded out by discussions of available published clinical guidelines. Outstanding chapters, able to stand alone as definitive reviews for all providers, are those addressing insomnia, attention deficit hyperactivity disorder (ADHD) and disruptive disorders in childhood and adolescence, chronic nonmalignant pain, and depression and dementia-related disorders in the elderly. This book is an important milestone in the quest to better predict and achieve therapeutic outcomes in the management of mental illness with well-studied medication and behavioral interventions. It will be exciting to see where the second edition of this important first round will lead us.

James H. Bray, PhD
Former President of the American Psychological Association and American Society for Advancement of Pharmacotherapy.

Kelly L. Cozza, MD, DFAPA, FAPM1
Associate Professor, Department of Psychiatry
Director, Psychiatry Clinical Clerkship
Scientist, Center for the Study of Traumatic Stress
Uniformed Services University of the Health Sciences
Bethesda, Maryland

References

1. Agency for Healthcare Research and Quality (AHRQ) (2017). Behavioral and mental health. Retrieved from http://www.ahrq.gov/professionals/prevention-chronic-care/improve/mental/index.html
2. American Psychological Association (APA) (2016). Data on behavioral health in the United States. Retrieved from http://www.apa.org/helpcenter/data-behavioral-health.aspx
3. Dunlop, B. W., Rajendra, J. K., Craighead, W. E., Kelley, M. E., McGrath, C. L., . . . & Mayberg, H. S. (2017). Functional connectivity of the subcallosal cingulate cortex and differential outcomes to treatment with cognitive-behavioral therapy or antidepressant medication for major depressive disorder. AJP in Advance, 1–13. doi:10.1176/appi.ajp.2016.16050518
4. Kessler, R. C., Angermeyer, M., Anthony, J. C., De Graff, R., Demyttenaere, K., Gasquet, I., . . . & WHO World Mental Health Survey Consortium (2007). Lifetime prevalence and age of onset distributions of mental disorders in the World Health Organization's World Mental health Survey Initiative. Word Psychiatry, 6, 168–176.
5. Library of Congress (2000). Project on the decade of the brain. Retrieved from http://www.loc.gov/loc/brain/
6. Morris, K. (2000). Advances in “brain decade” bring new challenges. Lancet, 355, 45....

Produkt-Details

• Erscheint lt. Verlag: 12.10.2017
• Sprache: englisch
• Themenwelt: Geisteswissenschaften ► Psychologie ► Klinische Psychologie
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie
• Schlagworte: biopsychosocial interventions • biopsychosocial interventions for psychoses • bipolar disorder biopsychosocial treatments • Clinical psychology • cognitive behavioral psychopharmacology • Cognitive Behavioral Therapy • Cognitive behavioral therapy (CBT) • combined psychopharmacology and psychotherapy • evidence-based biopsychosocial interventions • integrated biopsychosocial treatment for depression • integrated biopsychosocial treatment of adhd • integrated biopsychosocial treatment of adjustment disorder • integrated biopsychosocial treatment of anxiety disorders • integrated biopsychosocial treatment of chronic, persistent, non-malignant pain • integrated biopsychosocial treatment of disruptive disorder • integrated biopsychosocial treatment of dysthymia • integrated biopsychosocial treatment of eating disorders • integrated biopsychosocial treatment of geriatric disorders</p> • integrated biopsychosocial treatment of personality disorders • integrated biopsychosocial treatment of sleep disorders • integrated biopsychosocial treatment of somatoform disorders • integrated biopsychosocial treatments for mood disorders • integrating psychiatric drugs and psychotherapy • Klinische Psychologie • Kognitive Verhaltenstherapie • <p>combined treatment in mental health • Medical Science • Medizin • Psychiatrie • Psychiatry • Psychologie • Psychology • psychopharmacological interventions • Psychopharmacology • Psychotherapie • Psychotherapie u. Beratung • psychotherapy • Psychotherapy & Counseling • standalone treatment vs combined treatment in psychiatry
• ISBN-10: 1-119-15258-5 / 1119152585
• ISBN-13: 978-1-119-15258-3 / 9781119152583